Home›Stock Screener›Parmax Pharma

Parmax Pharma Share Price Today | Stock Price & Parmax Pharma Share Screener

PARMAX Pharmaceuticals
Live Share Price BSE
₹137.75
▲ 1.35 (0.99%)
2026-09-28 00:00:00

As of September 28, 2026, the live Parmax Pharma share price (BSE: PARMAX) is ₹137.75, up 0.99% from the previous close, with shares trading between ₹136.95 and ₹137.75 in today's trading session, and a 52-week range of ₹25.22–₹137.75. Check Parmax Pharma yearly highs lows for the annual price range and momentum. Use the Parmax Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Parmax Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹20 and net income of ₹-1, an operating margin of -26.0% and a profit margin of -5.0%.

Parmax Pharma Market Cap ₹45.61 Cr.
PARMAX P/E Ratio (TTM) -10.80
Parmax Pharma P/B Ratio -6.55
EPS (TTM) ₹-11.12
Dividend Yield -
Debt to Equity -
PARMAX 52 Week High ₹137.75
Parmax Pharma 52 Week Low ₹25.22
Operating Margin -26.00%
Profit Margin -5.00%
PARMAX Revenue (TTM) ₹20.00
EBITDA -
Net Income ₹-1.00
Total Assets ₹28.00
Total Equity ₹-6.00

Parmax Pharma Share Price Chart

Track the current stock price of Parmax Pharma with an interactive chart. Analyse PARMAX share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Parmax Pharma stock quote in one place.

The quote of ₹137.75 sits between the 52-week low of ₹25.22 and the 52-week high of ₹137.75, and the latest session moved 0.99% from the previous close.

Parmax Pharma Company Profile - Fundamental Screener

Screen Parmax Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for PARMAX shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE240T01014.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE240T01014

Parmax Pharma Balance Sheet Screener

Screen PARMAX balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹28, up from ₹19 in 2025.

Latest statistics put total assets at ₹28 and shareholder funds at ₹-6.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 28 19 15 18 18 23 21 20 17 8
Current Assets 17 10 6 8 7 10 9 9 9 4
Fixed Assets 8 8 9 10 10 11 10 5 6 3

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 12 8 6 5 5 6 5 5 2 1
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity -6 -2 0 6 6 6 5 5 5 5
Share Capital 4 5 5 5 5 5 5 5 5 5
Reserves & Surplus -11 -6 -4 1 2 1 1 0 0 0

Parmax Pharma Income Statement Screener - Profit & Revenue Analysis

Screen Parmax Pharma income statement and profit fundamentals. Analyze PARMAX quarterly results. Parmax Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹20 and net profit was ₹-1, equal to earnings per unit of ₹-3.20, at an operating margin of -26%.

In that period expenses were ₹21, interest cost ₹1 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹12 and net profit of ₹-6.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March

Revenue and Expenses

Revenue 20 12 28 11 16 18 26 21 12 12 0 0
Expenses 21 16 28 14 13 16 23 19 11 11 0 0

Operating Costs and Margins

EBITDA 0 -4 0 -3 2 3 4 2 1 1 0 0
Operating Profit % -26.00% -30.00% 1.00% -31.00% 15.00% 14.00% 13.00% 8.00% 9.00% 9.00% 0.00% 0.00%
Depreciation 1 1 1 2 2 2 2 1 1 1 0 0
Interest 1 1 1 1 0 0 0 0 0 0 0 0

Profit and Earnings

Profit Before Tax -3 -6 -2 -6 0 0 1 1 0 0 0 0
Tax 0 0 0 0 0 0 1 0 0 0 0 0
Net Profit -1 -6 -2 -6 0 0 1 0 0 0 0 0
EPS -3.20 -11.12 -5.60 -34.56 -0.28 0.38 2.02 1.15 0.21 0.00 -0.02 -0.01

Parmax Pharma Cash Flow Screener - Liquidity Fundamentals

Screen PARMAX cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2025-March, operating activities used ₹1.

Over the same period, investing activities used ₹1 and financing activities provided ₹1.

Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March

Cash from Operations and Investing

Operating Activities -1 0 0 1 4 3 1 4 -1 0
Investing Activities -1 -2 -1 -2 -3 -2 -3 -4 0 0

Financing and Net Cash

Financing Activities 1 1 0 -1 0 0 3 1 1 0
Net Cash Flow 0 0 -1 -2 1 0 1 1 0 0

Parmax Pharma Shareholding Pattern Screener

See Parmax Pharma shareholding pattern with promoter, FII, and DII holdings. Check Parmax Pharma promoter holding and ownership changes for PARMAX on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 30.80%, foreign institutions 0.00%, domestic institutions 0.00% and the public 63.10%, spread across 2,388 shareholders.

The shareholder count was 2,388 in 2026-Mar, compared with 2,273 in 2026-Jun.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun

Promoter Holding

Promoter Holding 30.80% 30.80% 30.80% 30.80% 30.80% 30.80% 30.83% 30.80%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 63.10% 56.25% 63.10% 63.10% 63.09% 63.08% 65.34% 65.78%
Other Holding 6.09% 12.95% 6.10% 6.10% 6.11% 6.12% 3.83% 3.42%
Shareholder Count 2,388 2,273 2,356 2,377 2,399 2,393 2,099 2,185

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Parmax Pharma. Parmax Pharma dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Parmax Pharma.

Parmax Pharma Stock Index Membership - Nifty & Sensex

See which indices include Parmax Pharma stock. Check PARMAX index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Parmax Pharma is not part of any tracked indices.
Only major market indices are tracked in our system.

Parmax Pharma Market Events Screener - Corporate Actions

Get Parmax Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Parmax Pharma stock events that may affect PARMAX share price, along with derivatives, futures and options activity and sector gainers.

12 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated August 14, 2026, with a record date of August 14, 2026.

It is followed by Extraordinary General Meeting dated July 2, 2026 and Quarterly Result Announcement dated June 2, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-08-14 2026-08-14 Quarterly Result Announcement NA 6.06%
2026-07-02 2026-07-02 Extraordinary General Meeting NA 74.22%
2026-06-02 2026-06-02 Quarterly Result Announcement NA 2.90%
2026-05-27 2026-05-27 Extraordinary General Meeting NA 26.25%
2026-02-14 2026-02-14 Quarterly Result Announcement NA -1.72%
2025-11-17 2025-11-17 Quarterly Result Announcement NA -1.84%
2025-09-30 2025-09-30 Annual General Meeting NA -3.64%
2025-08-14 2025-08-14 Quarterly Result Announcement NA 2.12%
2025-05-30 2025-05-30 Quarterly Result Announcement NA -1.09%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -5.75%
2024-11-14 2024-11-14 Quarterly Result Announcement NA 4.73%
2024-09-30 2024-09-30 Annual General Meeting NA 11.04%

Parmax Pharma Competitors Screener - Peer Stocks Comparison

Screen PARMAX competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 450,547 37.28 61,674 12.69% 11,565 34.94
Divis Laboratories 227,321 77.10 11,067 13.95% 2,568 71.94
Torrent Pharmaceuticals 189,499 86.36 13,886 20.34% 2,138 50.31
Cipla 115,772 34.42 29,045 2.24% 3,870 44.50
Zydus Life Science 112,527 24.59 27,658 17.64% 5,026 49.84
Lupin 101,611 18.61 29,039 26.75% 5,356 34.85
Mankind Pharma 98,797 47.94 14,636 14.85% 1,938 38.70
Dr Reddys Laboratories 98,324 31.25 35,059 3.90% 4,158 46.88
Laurus Labs 98,297 89.15 6,868 22.01% 890 64.41
Aurobindo Pharma 94,362 25.43 34,145 5.56% 3,503 56.48

Parmax Pharma Company Announcements - News & Reports Screener

Screen PARMAX latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated .

The next most recent announcements are dated October 5, 2026 and October 5, 2026.

Date Update Actions
Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-05 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-10-05 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-10-03 Announcement under Regulation 30 (LODR)-Change in Management -
2026-10-03 Results For Quarter Ended June 30 2026 -
2026-10-03 Board Meeting Outcome for Approval Of Unaudited Financial Results For Quarter Ended 30.06.2026 -
2026-10-02 Disclosures under Reg. 18(6) of SEBI (SAST) Regulations 2011 -
2026-09-29 Board Meeting Intimation for Approval Of Quarterly Financial Results For Quarter Ended June 30 2026 -
2026-07-29 Updates on Open Offer -
2026-07-27 Updates on Open Offer -
2026-07-27 Updates on Open Offer -
2026-07-22 Letter of Offer -
2026-07-16 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-07-03 Shareholder Meeting / Postal Ballot-Scrutinizer"s Report -
2026-07-02 Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association -
2026-07-02 Shareholder Meeting / Postal Ballot-Scrutinizer"s Report -
2026-07-02 Shareholder Meeting / Postal Ballot-Outcome of EGM -
2026-06-29 Closure of Trading Window -
2026-06-25 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-06-23 Corrigendum To The Notice Of (2Nd/2026-27) Extraordinary General Meeting Of The Company -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹137.75, within a 52-week range of ₹25.22 to ₹137.75. The P/E ratio is -10.80 and the P/B ratio is -6.55, with earnings per unit of ₹-11.12. Market capitalisation stands at ₹45.61 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 12 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.